30-day risk for death\/MI increased with lower hemoglobin thresholds for transfusion in patients with acute MI, anemia<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 1, 2024 (HealthDay News) — For patients with acute myocardial infarction (MI) and anemia, 30-day risks for death or recurrent MI seem to increase with lower hemoglobin thresholds for transfusion, according to a study published online Oct. 1 in the Annals of Internal Medicine<\/em>.<\/p>\n Gerard T. Portela, Ph.D., from the University of Pittsburgh, and colleagues estimated the efficacy of four individual hemoglobin thresholds (<10 g\/dL, <9 g\/dL, <8 g\/dL, and <7 g\/dL) to guide transfusion in patients with acute MI and anemia in a secondary analysis of the Myocardial Ischemia and Transfusion (MINT) trial conducted in 144 sites in six countries. Data were included for 3,492 MINT trial participants with acute MI.<\/p>\n The researchers found that the 30-day risk for death or recurrent MI (death\/MI) was 14.8, 15.1, 15.9, and 18.3 percent for a <10-g\/dL, <9-g\/dL, <8-g\/dL, and <7-g\/dL strategy, respectively. Relative to the <10-g\/dL strategy, the absolute risk differences and risk ratios increased as thresholds decreased, although the 95 percent confidence intervals were wide. Similar and imprecise findings were seen for 30-day death.<\/p>\n “The imprecision of these estimates, however, prevents explicit recommendations about individual hemoglobin transfusion thresholds,” the authors write.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n